Zhong Yuanchen, Chen Feifei, Chen Dianyan, He Qian, Zhang Xiaofei, Lan Lefu, Yang Chunhao
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 310024, Hangzhou, China.
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, 201203, Shanghai, China.
NPJ Antimicrob Resist. 2025 Apr 12;3(1):28. doi: 10.1038/s44259-025-00098-z.
UDP-N-acetylglucosamine-undecaprenyl-phosphate N-acetylglucosaminephosphotransferase (TarO) has been found to simultaneously contribute to β-lactam resistance and virulence of Methicillin-resistant Staphylococcus aureus (MRSA). However, optimization of hit compounds targeting TarO has been hindered due to their high lipophilicity and the poor correlation between the enzyme activity inhibition and β-lactam sensitization. In this study, 31 analogues of Tarocin A were designed, synthesized and evaluated by a luminescence-based reporter preliminary screening. In the subsequent β-lactams synergy test, a good correlation was observed between the results obtained from these two methods. Finally, analog 18a with more potential against TarO and an improved hydrophilicity (clogP = 3.2) was obtained. Compared with Tarocin A, 18a shows stronger β-lactam sensitizing and anti-biofilm activities in vitro, as well as potent anti-virulence and synergistic potency with imipenem in vivo. These results suggest that TarO is a promising target for combating MRSA, and 18a can serve as a lead molecule.
已发现UDP-N-乙酰葡糖胺-十一异戊烯磷酸N-乙酰葡糖胺磷酸转移酶(TarO)同时有助于耐甲氧西林金黄色葡萄球菌(MRSA)的β-内酰胺抗性和毒力。然而,由于靶向TarO的命中化合物具有高亲脂性以及酶活性抑制与β-内酰胺致敏之间的相关性较差,因此对其优化受到阻碍。在本研究中,设计、合成了31种Tarocin A类似物,并通过基于发光的报告基因初步筛选进行评估。在随后的β-内酰胺协同试验中,观察到这两种方法获得的结果之间具有良好的相关性。最后,获得了对TarO更具潜力且亲水性有所改善(clogP = 3.2)的类似物18a。与Tarocin A相比,18a在体外表现出更强的β-内酰胺致敏和抗生物膜活性,以及在体内具有强大的抗毒力和与亚胺培南的协同效力。这些结果表明,TarO是对抗MRSA的一个有前景的靶点,且18a可作为先导分子。